Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9217908 | 0.86 | STS (0.44) | LMNAMAPTHTTALDH1A1POLB | |
| SCHEMBL7922665 | 0.84 | CSNK2A1 (0.46) | ALDH1A1 | |
| SCHEMBL12603661 | 0.84 | HTT (0.45) | TP53GAALMNAMAPTHTT | |
| SCHEMBL3493018 | 0.83 | HSD11B1 (0.46) | SRCTGFBR1ABCB1LMNAMAPT | |
| SCHEMBL9472224 | 0.83 | ELANE (0.53) | GAAABCB1LMNAMAPTHTT | |
| SCHEMBL5937228 | 0.81 | CYP46A1 (0.43) | LMNAMAPTHTTALDH1A1NPSR1 | |
| SCHEMBL15403132 | 0.79 | TP53 (0.55) | TP53GAASRCTGFBR1ABCB1 | |
| SCHEMBL30785077 | 0.79 | TP53 (0.66) | TP53GAASRCTGFBR1ABCB1 | |
| SCHEMBL3964231 | 0.79 | TP53 (0.66) | TP53GAASRCTGFBR1ABCB1 | |
| SCHEMBL6647431 | 0.79 | TDP1 (0.47) | LMNAMAPTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101448791-B | Fxr agonists | LILLY CO ELI | 2011-11-16 | — | — | CN | disclosed |
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090270460-A1 | FXR AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-10-29 | — | — | US | disclosed |
| CN-101448791-A | FXR agonists | LILLY CO ELI (US) | 2009-06-03 | — | — | CN | disclosed |
| EP-2029547-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140183-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270460-A1 | FXR AGONISTS | NR1H4, SLC10A1, GPBAR1 | TP53 4727/4885GAA 745/4885SRC 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.